HIKMA Pharmaceuticals PLC — Major Shareholding Notification 2016

Feb 11, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8170O

Hikma Pharmaceuticals Plc

11 February 2016

Notification of major interests in shares

LONDON, 11 February 2016 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK), the fast growing multinational pharmaceuticals group, announces as follows:

1	Identity of the issuer or the underlying issuer of existing shares to which the voting rights are attached	Hikma Pharmaceuticals PLC

2	Reason for the notification
	An acquisition or disposal of voting rights	Yes
	An acquisition or disposal of financial instruments which may result in the acquisition of shares already issues to which voting rights are attached	No
	An event changing the breakdown of voting rights	No
	Other (please specify): Compliance with the Transparency Directive	No

3	Full name of the person subject to the notification obligation					Vanguard Healthcare Fund
4	Full name of shareholders					Vanguard Healthcare Fund
5	Date of the Transaction (and date on which the threshold crossed is reached differently)					8 February 2016
6	Date on which the issuer notified					10 February 2016
7	Threshold that is crossed					3%
8	Notified details					See A, B & C below
A. Voting rights attached to shares
Class type of shares (if possible using the ISIN code)		Situation previous to the triggering transaction		Resulting situation after the triggering transaction
Number of shares	Number of voting rights	Number of shares	Number of voting rights			% of voting rights
Direct	Direct		Indirect	Direct	Indirect
Ordinary Shares (0.10 GBP) GB00B0LCW083		5,912,554	5,912,554	6,008,846	6,008,846				3.01%

B. Qualifying Financial instruments
Resulting situation after the triggering transaction
Type of financial instrument	Expiration Date	Exercise/Conversion Period/Date	Number of voting rights that may be acquired if the instrument if exercised/converted	% of voting rights
-	-	-	-	-

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument	Exercise Price	Expiration Date	Exercise/Conversion Period/Date	Number of voting rights instrument refers to	% of voting rights
Nominal	Delta
-	-	-	-	-	-	-

Total A+B+C
Number of Voting rights	% of voting rights
6,008,846	3.01

9

Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable

N/A

Proxy Voting
10	Name of the proxy holder	N/A
11	Number of voting rights proxy holder will cease to hold:
12	Date on which proxy holder will cease to hold voting rights:

13	Additional Information
14	Contact name:	Vanguard Health Care Fund c/o The Vanguard Group, Inc. Vanguard_Fund_Compliance@Vanguard.com
15	Contact telephone number:	+001 (610) 669-8989

- ENDS -

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.  In 2014, Hikma achieved revenues of $1,489 million and profit attributable to shareholders of $278 million. 

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLUASURNUAUAAR